What is a potential treatment option for tardive dyskinesia in patients who must remain on antipsychotic medications?

Prepare for the Psychiatry Core Exam. Enhance your knowledge with flashcards and multiple choice questions, each offering hints and explanations for a better understanding. Ace your test with confidence!

Tardive dyskinesia is a movement disorder characterized by involuntary, repetitive body movements, often as a side effect of long-term antipsychotic medication use. VMAT2 inhibitors have emerged as a specific treatment option for this condition. These medications, such as deutetrabenazine and tetrabenazine, work by inhibiting the vesicular monoamine transporter 2 (VMAT2), which helps to reduce the release of monoamines, including dopamine. This mechanism can help alleviate the involuntary movements associated with tardive dyskinesia, making it a targeted and effective approach for managing this condition in patients who continue to need antipsychotic medications for their underlying mental health issues.

In contrast, other options such as beta-blockers, SSRIs, and electroconvulsive therapy, while useful in various psychiatric conditions, do not specifically address the mechanism or symptoms of tardive dyskinesia effectively. Beta-blockers might help with certain movement disorders but are not first-line treatments for tardive dyskinesia, and SSRIs are primarily used for mood disorders. Electroconvulsive therapy is a powerful treatment for severe psychiatric illnesses but is not indicated solely for tardive dyskinesia. Thus, VMAT2 inhibitors